Dual-drug combination shows promise against diabetic eye disease in animal model

February 15, 2017 by Doug Bennett, University of Florida

A two-drug cocktail provided better protection against diabetes-related vision loss than a single drug during testing in rat models, a team of University of Florida Health and Dutch researchers has found.

Researchers say the drug combination is a promising and unique potential treatment for patients with , a major cause of vision loss in middle-age diabetes patients. Diabetic retinopathy damages blood vessels in the retina at the back of the eye, leading to distorted vision or blindness. There were 4.2 million cases of diabetic retinopathy among people ages 40 and over in the United States, according to a 2016 estimate by the American Academy of Ophthalmology.

Now, researchers from UF and the Erasmus Medical Center in the Netherlands have shown that the two drugs were more effective than a single drug at reducing the symptoms of diabetic retinopathy within the animals' retinas. The findings were published recently in the journal Investigative Ophthalmology & Visual Science.

During the 12-week study, the two-drug treatment reduced capillary loss by 68 percent compared with 43 percent with the single drug. Known as angiotensin receptor neprilysin inhibitor, or ARNI, the cocktail is a combination of irbesartin (an )—a medication already being used to treat high blood pressure—and the anti-diarrhea compound thiorphan, a neprilysin inhibitor. In the laboratory, its effectiveness was compared with using irbesartin alone.

The two drugs did not completely reverse the effects of diabetic retinopathy, but they slowed it in the animal models, said Tuhina Prasad, Ph.D., a postdoctoral associate in the UF College of Medicine's department of ophthalmology research and a co-author of the paper. Most significantly, Prasad said the two drugs were much more effective at decreasing inflammation, which is one of the main symptoms of diabetic retinopathy.

"If you can decrease that inflammation, it protects the retinal cells and delays the progression of the disease," Prasad said.

The two-drug combination was also more effective than the lone drug at reducing cell death in the retina after 12 weeks in the rat models. The two drugs produced a 51 percent reduction in cell death, while the single showed only a 25 percent reduction, according to the findings. That is potentially significant in the development of drugs to treat diabetic retinopathy because the disease is strongly associated with prolonged diabetes in patients, the researchers noted.

Before a treatment can be brought to patients, researchers still have some work ahead: The possible chronic side effects of the neprilysin enzyme inhibitor on the eye have yet to be studied. Likewise, the long-term effects of giving that inhibitor are still unknown.

Still, Prasad said, the newly discovered compound may someday be a promising option for the millions of people living with diabetic retinopathy.

Explore further: Growth factor shown to protect the retina in early stage diabetes

Related Stories

Growth factor shown to protect the retina in early stage diabetes

February 2, 2017
Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have shown that a slight increase in transforming growth factor beta (TGF-β), which is present in preclinical animal models with diabetic ...

Lucentis approved for diabetic retinopathy

February 9, 2015
(HealthDay)—A drug to treat the most common eye disease among diabetics has been approved by the U.S. Food and Drug Administration.

Researchers find vessel damage may precede diabetic retinopathy

April 27, 2016
A University of Iowa-led study of diabetes-related vision impairment holds good news—and some bad news—for patients with signs of these disorders.

Researchers identify candidate biomarker of accelerated onset diabetic retinopathy

April 1, 2016
Researchers from Massachusetts Eye and Ear and Schepens Eye Research Institute have shown an association between a defective myogenic response—the regulatory increase or decrease in blood pressure to keep blood flow within ...

Nearly six in ten diabetics skip eye exams, study finds

November 10, 2016
(HealthDay)—Almost two-thirds of people with diabetes don't get annual eye exams, despite having an increased risk for serious eye disease and vision loss, researchers say.

Researchers discover heart drug could reduce diabetes related blindness

June 14, 2016
Researchers at Queen's University Belfast and University College London have discovered that a drug, originally developed to treat cardiovascular disease, has the potential to reduce diabetes related blindness.

Recommended for you

An orange a day keeps macular degeneration away: 15-year study

July 12, 2018
A new study has shown that people who regularly eat oranges are less likely to develop macular degeneration than people who do not eat oranges.

Injectable electronics offer powerful new tool in understanding how retinal cells work

June 28, 2018
Charles Lieber and his group are rewriting the rules of how scientists study retinal cells, and they're doing it with a single injection.

Why the eye could be the window to brain degeneration such as Alzheimer's disease

June 26, 2018
Researchers from Queen's University Belfast have shown for the first time that the eye could be a surrogate for brain degeneration like Alzheimer's disease (AD).

Microglia protect sensory cells needed for vision after retinal detachment

June 18, 2018
A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the brain and retina, play a protective role in response to retinal detachment. Retinal detachment and subsequent degeneration ...

161 genetic factors for myopia identified

June 15, 2018
The international Consortium for Refractive Error and Myopia (CREAM) recently published the largest-ever genetic study of myopia in Nature Genetics. Researchers from the Gutenberg Health Study at the Medical Center of Johannes ...

Normal eye dominance is not necessary for restoring visual acuity in amblyopia

June 7, 2018
Amblyopia, commonly known as "lazy eye," is a visual disorder common in children. The symptoms often are low acuity in the affected or "lazy" eye and impaired depth perception. Researchers have long believed that the impaired ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.